All In MedTech

Device Trial Radar · NCT05683691

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR

Last checked: Nov 20, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

May 16, 2023

Primary completion

Apr 2027

Study completion Apr 2029

Sponsor

Lead sponsor
Francis Medical Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 13, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • Vanquish SystemDevice

    Water vapor ablation delivered transurethrally in patients with intermediate risk, localized prostate cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness EndpointTime frame: 36 months
  2. Primary Safety EndpointTime frame: 12 months

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic- Phoenix

    Phoenix, Arizona

  • Memorial Care

    Laguna Hills, California

  • University of Southern California

    Los Angeles, California

22 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.